Table 2.
Comparison of qualitative features between grades and stages
| Feature |
Grade |
ENETS TNM stage1 |
||||||
| Total | G12 | G2-32 | P value | Total | I/II2 | III/IV2 | P value | |
| Location | 0.094 | 0.059 | ||||||
| Head | 24 | 11 (45.8) | 13 (54.2) | 23 | 7 (30.4) | 16 (69.6) | ||
| Body | 25 | 18 (72) | 7 (28) | 22 | 14 (63.6) | 8 (36.4) | ||
| Tail | 6 | 2 (33.3) | 4 (66.7) | 6 | 4 (66.7) | 2 (33.3) | ||
| Margins | < 0.001 | < 0.001 | ||||||
| Well defined | 39 | 28 (71.8) | 11 (28.2) | 35 | 24 (68.6) | 11 (31.4) | ||
| Ill defined | 16 | 3 (18.8) | 13 (81.2) | 16 | 1 (6.2) | 15 (93.8) | ||
| Vasc. infiltration | 0.022 | - | - | - | - | |||
| Present | 7 | 1 (14.3) | 6 (85.7) | |||||
| Absent | 48 | 30 (62.5) | 18 (37.5) | |||||
| Liver metastases | 0.002 | - | - | - | - | |||
| Present | 7 | 0 (0) | 7 (100) | |||||
| Absent | 48 | 31 (64.6) | 17 (35.4) | |||||
| Atrophy3 | 0.446 | 0.151 | ||||||
| Present | 13 | 7 (53.8) | 6 (46.2) | 13 | 4 (30.8) | 9 (69.2) | ||
| Absent | 36 | 22 (61.1) | 14 (38.9) | 32 | 17 (53.1) | 15 (46.9) | ||
| MPD dilation4 | 0.215 | 0.151 | ||||||
| Present | 13 | 6 (46.2) | 7 (53.8) | 13 | 4 (30.8) | 9 (69.2) | ||
| Absent | 36 | 23 (63.9) | 13 (36.1) | 32 | 17 (53.1) | 15 (46.9) | ||
| CBD dilation4 | 0.264 | 0.275 | ||||||
| Present | 7 | 2 (28.6) | 5 (71.4) | 7 | 1 (14.3) | 6 (85.7) | ||
| Absent | 17 | 9 (52.9) | 8 (47.1) | 16 | 6 (37.5) | 10 (62.5) | ||
1
Four lesions were excluded from this analysis (minimally invasive surgery without lymphadenectomy);
2
Number of cases/cases in row;
3
Pancreatic head/body lesions;
4
Pancreatic head lesions. Data are presented as numbers of cases. ENETS: European Neuroendocrine Society; TNM: Tumor-nodes-metastases.